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Abstract
Background: Chronic obstructive pulmonary disease (COPD) has substantial economic and human costs; it is
expected to be the third leading cause of death worldwide by 2030. To minimize these costs high quality
guidelines have been developed. However, guidelines alone rarely result in meaningful change. One method of
integrating guidelines into practice is the use of clinical pathways (CPWs). CPWs bring available evidence to a range
of healthcare professionals by detailing the essential steps in care and adapting guidelines to the local context.
Methods/design: We are working with local stakeholders to develop CPWs for COPD with the aims of improving
care while reducing utilization. The CPWs will employ several steps including: standardizing diagnostic training,
unifying components of chronic disease care, coordinating education and reconditioning programs, and ensuring
care uses best practices. Further, we have worked to identify evidence-informed implementation strategies which
will be tailored to the local context.
We will conduct a three-year research project using an interrupted time series (ITS) design in the form of a multiple
baseline approach with control groups. The CPW will be implemented in two health regions (experimental groups) and
two health regions will act as controls (control groups). The experimental and control groups will each contain an urban
and rural health region. Primary outcomes for the study will be quality of care operationalized using hospital readmission
rates and emergency department (ED) presentation rates. Secondary outcomes will be healthcare utilization and
guideline adherence, operationalized using hospital admission rates, hospital length of stay and general practitioner (GP)
visits. Results will be analyzed using segmented regression analysis.
Discussion: Funding has been procured from multiple stakeholders. The project has been deemed exempt from ethics
review as it is a quality improvement project. Intervention implementation is expected to begin in summer of 2017.
This project is expected to improve quality of care and reduce healthcare utilization. In addition it will provide evidence
on the effects of CPWs in both urban and rural settings. If the CPWs are found effective we will work with all
stakeholders to implement similar CPWs in surrounding health regions.
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Background
Chronic obstructive pulmonary disease (COPD) is a re-
spiratory syndrome characterized by progressive, partially
reversible airway obstruction and lung hyperinflation [1].
This results in increasingly frequent and severe exacerba-
tions [1]. COPD results in a substantial human and eco-
nomic burden both within Canada and internationally.
Although best practices have been developed to minimize
this burden [1–4], implementation of these practices is
generally fragmented [3]. In response to this fact, this
protocol outlines the process of improving quality of care
in two Saskatchewan health regions through the imple-
mentation of locally tailored clinical pathways (CPWs)
and the subsequent evaluation of these CPWs.
Prevalence
COPD is most often caused by smoking tobacco [5], but
is also associated with air pollution [5] and occupational
exposures to dusts and chemicals [5]. The disease is
somewhat unique in the fact that it is generally under-
diagnosed [6, 7]. This has led to difficulties in estimating
prevalence at both the international and national level.
Estimates for worldwide prevalence of COPD range from
4% to 20% [6]. Similar trends can be seen in Canada
where approximately 4% of Canadians self-report as
being diagnosed [7] but estimates based on airflow
obstruction suggest a prevalence between 12% and
17% depending on diagnostic criteria [7]. The prov-
ince of Saskatchewan has a prevalence similar to the
national self-reported rate with an age standardized
estimate of 4.3% [8].
Disease burden
Although prevalence is difficult to determine it is clear
that COPD is responsible for an enormous human bur-
den, both internationally and within Canada. This is il-
lustrated by estimates suggesting that internationally the
disease will be the third leading cause of death by 2030
[6]. Within Canada COPD accounts for the highest rate
of hospital admissions among major chronic illnesses
[9]. This results in substantial financial costs, with direct
costs estimated at CAD $2.02 billion in 2010 [10], a
number expected to increase to CAD $4.6 billion by
2030 [10]. These estimates more than double when in-
direct costs are taken into account [10].
Evidence based recommendations
In order to minimize the burden of COPD, high quality
guidelines have been developed [1–4]. These guidelines
generally specify disease identification through spirometry,
management through a combination of smoking cessa-
tion, vaccination, pharmacologic therapy and physical ac-
tivity, and proper management of COPD exacerbations
(aeCOPD) with pharmacologic therapy [11]. When imple-
mented, these steps have shown substantial improvements
in patient quality of life, as well as a reduction in health-
care utilization. These benefits have been demonstrated in
the Saskatoon Health Region (SHR) where the application
of best practices through the LiveWell COPD program
resulted in a 65% reduction in hospital admissions, a 61%
reduction in inpatient days and a 44% reduction in emer-
gency room visits [12].
Although these results are promising, evidence suggests
that the creation of guidelines is inadequate [13–15] as
passive dissemination alone rarely results in changes in
practice [3, 16, 17]. Estimates across the healthcare envir-
onment suggest that 30–40% of patients do not receive
treatments with proven effectiveness [18].
Clinical pathways (CPWs)
One promising method of minimizing this gap is the im-
plementation of clinical pathways (CPWs). CPWs, also
known as integrated care pathways or clinical protocols,
are tools used by health professionals to guide evidence-
based practice and improve the interaction between
health services. They bring the available evidence to a
range of healthcare professionals by adapting guidelines
to a local context and detailing the essential steps in the
assessment and care of patients [19, 20].
Evidence exists to support the use of CPWs to change
behaviour and improve quality of care [14, 15, 21–23]. A
Cochrane systematic review on the use of CPWs in hospi-
tals indicates that CPWs reduce in-hospital complications
and improve documentation [24]. Recent studies regard-
ing the use of CPWs for the management of COPD follow
this positive trend, a fact evidenced by reported reductions
in: hospitalization rates [25], readmission rates [25], length
of stay [26], in-hospital complications [26], and increased
preventative consultations [27]. However, studies generally
fail to show a reduction in mortality [25, 26].
A review specific to the use of CPWs to improve in-
hospital management of aeCOPD also found indications
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of positive results [28]. The review demonstrates evidence
of improvements regarding: blood sampling, daily weight
measurement, arterial blood gas measurement, referral to
rehabilitation, feelings of anxiety, length of stay, readmis-
sion, and in-hospital mortality [28]. However, the authors
suggest that results should be interpreted with caution as
the review only included four studies. Further, these stud-
ies used a heterogeneous group of indicators and often
failed to report statistics [28].
Although this limited group of studies shows some evi-
dence regarding the assessment of CPWs for COPD, little
has been done to determine the effects of CPWs within
the province of Saskathchewan where CPWs have already
been implemented for hip and knee surgeries [29], urogy-
necology assessments [30], treatment of prostate cancer
[29] and treatment of stroke [30]. To date none of these
pathways have been rigorously evaluated [29, 30].
Methods/design
Aims of the CPWs
In order to improve knowledge translation and address
the limited evidence on the effectiveness of CPWs we
will implement and evaluate two CPWs for the treat-
ment of COPD within the province of Saskatchewan.
The first CPW will be implemented in a predominently
urban health region (Regina Qu’Appelle; RQHR) and the
second will be implemented in a rural health region (to be
chosen following implementation in RQHR). The develop-
ment and implementation of the CPW will utilize the
following steps:
 Identify and current best practices for the diagnosis
and management of COPD;
 Use idenfied best practices in combination with local
resources in the development of two CPWs;
 Tailor evidence-informed implementation strategies
to the local context with the goal of encouraging
uptake of the developed CPWs;
 Implement and pilot test the COPD pathway in
two different Saskatchewan health regions; one
urban (RQHR) and one in a rural (to be chosen at
a later date);
 Evaluate the effectiveness of the CPWs based on
chosen outcomes;
 Improve on areas of weakness identified through the
evaluation
These steps are described in detail through the re-
mainder of the documents. By applying this process we
hope to achieve the following goals:
 Increase quality of care;
 Reduce healthcare utilization;
 Increase guideline adherence
To determine if these goals are met, the project will
utilize an interrupted time series (ITS) design with con-
trol groups. We will compare the health regions which
implement CPWs to both the control groups and to pre-
inteventions measures.
Foundational activities
To encourage the realization of these goals, the project
is based on a number of foundational activities. The
most substantial of these has been work to develop the
LiveWell COPD program in Saskatoon. The program
was initiated in 1999, but has benefitted from numerous
updates. The current delivery format was introduced in
2005. The pathways used in the program employ a number
of steps to improve quality of care. These include: standard-
izing diagnostic training through Lung Association of
Saskatchewan’s RESPTREC spirometry training program
[31], implementing and unifying common components of
chronic disease care in the health region, coordinating the
provision of education and reconditioning programs, and
ensuring disease specific care utilizes and delivers evidence-
informed practices. In addition, the LiveWell COPD pro-
gram has worked to standardize documentation and
improve in-hospital identification of COPD patients. The
knowledge and expertise gained through the development
and implementation of the LiveWell COPD program will
guide our development and implementation processes.
Further, we have developed a strong working relation-
ship with key stakeholders in the Regina Qu’Appelle
Health Region (RQHR). We are currently engaged with
these stakeholders to complete an updated systematic
review regarding the use of CPWs for COPD. To date
this has resulted in publication of a systematic review
protocol [32], identification of relevant studies and ex-
traction of data from these publications. This work has
been used to identify best practices in developing and
implementing a CPW for COPD. These best practices
will be used in CPW development and implementation
in both the urban and rural health regions.
Additionally, we have worked with this group to map
the relevant services available within RQHR. This was
done in order to 1) ensure that the CPW developed is
well adapted to the local context and utilizes and coordi-
nates currently available services; and 2) allows the re-
search team to identify current gaps in the care of
COPD patients and departures from best practices.
Implementation strategy
Based on data extraction outlined in the systematic re-
view protocol [32] we identified 12 evidence-informed
implementation strategies [24, 33–36]. A cursory de-
scription of these activities is presented in Table 1.
As CPWs require that interventions and implementa-
tion are adapted to the local context, we will develop an
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implementation scheme based on these strategies for each
health region. We are currently working to create an im-
plementation team in RQHR that includes a physician
lead and other local stakeholders to tailor implementation
strategies. A similar process will be used when the rural
health region is identified. Chosen implementation strat-
egies will be described in future publications.
Key stakeholders
This collaborative research project incorporates key stake-
holders to ensure the best possible outcomes. Three orga-
nizations are integral to the success. The first is the
continuous quality improvement teams from each health
region. Within the province, these have been referred to
as the Kaizen Promotion Office or Kaizen Operations
Teams. These teams are an essential resource in the
process of tailoring interventions to the local context. Sec-
ond, the Saskatchewan Health Quality Council (HQC) is
imperative, as representatives are able to amalgamate and
produce all data necessary for evaluation. Finally, leaders
in the LiveWELL COPD program in Saskatoon play a sig-
nificant role, as these individuals possess the historical
knowledge necessary to inform the development and con-
tinuous refinement of the CPW. Additional stakeholders
crucial to the realization of the project goals are: members
of the Saskatchewan Ministry of Health, Lung Association
of Saskatchewan and Telehealth services from each of the
regions as well as local clinicians such as: primary care
providers, respirologists, pharmacists and nurses. To en-
courage input from all stakeholders we have developed a
Table 1 Overview of evidence-informed implementation strategies
Implementation strategy Description
Development
Clinician involvement Utilization of individuals from all relevant professional groups [24, 33].
Evidence based interventions Development which emphasises the importance of linking recommendations
to the scientific research that supports them, identified through rigorous
systematic identification and appraisal of all relevant research [24, 33].
Local consensus processes Inclusion of participating providers in discussion to ensure that they agree
that the chosen clinical problem is important and the approach to managing
the problem is appropriate [34].
Analysis and Implementation Planning
Implementation team Utilization of a multidisciplinary change team. This team should include
representation from three different leadership levels: Senior Leadership,
Clinical/Technical Expertise, and Front-line Leadership [24, 34].
Identification of potential barriers to change Strategies to improve professional practice taking into account prospectively
identified barriers to change [24, 35, 36].
Identification of practice gaps Collection and analysis of data related to the need for the innovation; this
assessment is used for: the description of usual care and its distance from
evidence based care, outcomes of usual care, opinions from stakeholders
on the needs for an innovation, and/or special considerations for delivering
the innovation in the local context [24, 36].
Education
Local opinion leaders The use of providers nominated by their colleagues as educationally
influential [24, 33, 35].
Educational meetings The participation of healthcare providers in conferences, lectures,
workshops or traineeships [35].
Educational outreach The use of a trained individual who meets with providers in their
practice settings to give information with the intent of changing the
providers’ practice [34, 35].
Printed educational materials The distribution of published or printed recommendations for clinical care,
including clinical practice guidelines, audio-visual materials and electronic
publications [34, 35].
Systems
Audit and feedback Any summary of clinical performance of healthcare over a specified period,
which is intended to change health professional behaviour. Indexed by
objectively measured professional practice or healthcare outcomes [24, 35].
Reminders Patient or encounter specific information, provided verbally, on paper or
digitally. This information is intended to prompt a health professional
to recall information [24, 34, 35].
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representative working group from RQHR. A list of
current members of the working group and their expertise
is presented in Table 2. A similar team will be assembled
once a rural health region is chosen.
Design
We propose a quantitative health services research pro-
ject using an interrupted time series (ITS) design in the
form of a multiple baseline approach with control
groups [37]. This methodology allows post-intervention
trends to be compared with pre-intervention trends as
well as the control group. We will compare the health
regions which implement CPWs (intervention group) to
both health regions which have not implemented the
CPW (control group) and to pre-inteventions measures.
Specificially, we will look at changes in:
 Quality of care, measured by:
○ Hospital readmission rates;
○ Unscheduled visits (emergency department);
 Healthcare service utilization, measured by:
○ Admissions rates;
○ Length of stay;
 Adherence, measured by:
○ Scheduled visits (primary care providers,
specialists)
Primary outcome
The primary outcome for the study will be quality of
care provided in participating health regions. This will
be operationalized using hospital readmission rates and
emergency department (ED) presentation rates.
Secondary outcomes
The secondary outcomes of the study will be healthcare
utilization and guideline adherence. Healthcare utilization
will be operationalized using hospital admission rates
and hospital length of stay. Guideline adherence will
be operationalized as scheduled primary care provider
and specialist visits.
Analysis
Analysis will be conducted using segmented regression
analysis. This form of regression is used to control for
pre-existing trends by estimating changes in intercept and
slope after the introduction of the intervention. Both an
immediate impact (change in intercept) and gradual
changes over time (change in slope) can be detected [38].
This design is less susceptible to the common threats to
internal validity that occur in most observational study de-
signs, including maturation and regression to the mean.
We will report the β coefficients which measure the fol-
lowing variables: model intercept prior to implementation
(β0), model slope prior to implementation (β1), model
intercept following implementation (β2) and model slope
following implementation (β3). In this analysis a statisti-
cally significant β2 coefficient which is smaller than β0
suggests a decrease in the rate following the intervention.
Similarly, a statistically significant negative β3 coefficient
suggests a decrease in the rate of interest.
Sample size considerations
We used two years of existing readmissions data to con-
duct power calculations for the ITS design. This was done
using the simulation approach developed by Zhang et al.
[39]. We estimated the Mean Squared Error (MSE), base-
line intercept, and trend in the pre-intervention period
using the pre-intervention data. Further we assumed ei-
ther moderate or strong autocorrelation (AR(1) = 0.4 or
0.8); a change in intercept of 0, and two-sided α = 5%. We
varied the number of post-intervention observation points
from 6 to 30 and calculated the required change in slope
that can be detected with at least 80% power. The analysis
of the pre-intervention data showed strong secular trends
in the primary outcome measure. We anticipate that for
most outcomes, monthly observations will be used; in the
case of small denominators for some outcomes, we may
need to use quarterly or semi-annual intervals.
Based on these calculations we will use 36 pre- and
post-intervention data points for most outcomes (with a
minimum of 6 pre- and post-intervention data points for
Table 2 Working Group Members
Name Position
Sheila Anderson Director, Primary Health Care, Kaizen
Operations Team
Margaret Baker Executive Director Primary Health Care,
Ministry of Health
Bree Calland Program Development Educator,
Respiratory Services
Patricia Comfort Primary Health Care Manager, Chronic
Disease Prevention and Management
Lori Garchinski Executive Director, Medicine
Dr Rashaad Hansia Urban Primary Health Care Physician
Dyad Leader
Shannon Jackson Manager, Respiratory / Internal Medicine
Unit, Regina General Hospital
Rae-Lynn Lang Manager of Therapies, Acute Care
Taryn Lorenz Director, Medicine
Sheryl O’Quinn Manager, Respiratory Services
Dr Prakash Patel Respirologist
Erin Roesch Director, Primary Health Care Decision
Support
Dr Shabaz Sheikh Respirologist
Roberta Weist Director, HealthLine Saskatchewan
Dr Fouche Williams Rural Primary Health Care Physician
Dyad Leader
Tanya Winkel Pharmacist, Acute Care
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some secondary outcomes). As each data point for the
primary outcome will contain one month’s data this
equates to three years of pre-intervention and three
years of post-intervention data.
Settings
In order to evaluate the interventions, each health region
will be matched with a control. For the intervention
implemented in the Regina Qu’Appelle Health Region
(RQHR), Saskatoon Health Region (SHR) will act as the
control. Rural health regions will be chosen following
implementation in RQHR and will occur following
stakeholder consultation. As with the urban setting, the
chosen rural health region will be compared to an ap-
propriate control health region.
Data sources
Data regarding hospital admissions rates, hospital readmis-
sion rate and length of stay will be retrieved through the
Discharge Abstracts Database from the Canadian Institute
of Health Information (CIHI) [40]. Data regarding sched-
uled GP visits will be retrieved through the Saskatchewan
Health Quality Council Database. Data will be re-
trieved at the health region level and disaggregated to
the hospital level.
Discussion
Funding for the research has been awarded by the Lung
Health Institute of Canada, the Saskatchewan Ministry
of Health and through private industry (Novartis). The
Research Ethics Board deemed to the project to be exempt
from ethics review as the work conducted is a quality im-
provement project using automatically conducted and de-
identified data. The study has been registered through
clinicaltrials.gov (NCT03075709). Intervention implemen-
tation is expected to begin in RQHR in June 2017 with
preliminary meetings with rural stakeholders following.
Data collection will conclude 18 months after the start of
implementation for each health region.
Successful steps to improve quality of life and reduce
healthcare utilization have already been taken in some
Saskatchewan health regions; however, these successes
have not yet been replicated across the province. This
has left substantial disparities in health outcomes for
COPD patients among the province’s health regions. We
aim to take the first steps to abate these differences by
implementing a CPW in two Saskatchewan health regions.
In addition to increasing the quality of care received
by COPD patients, this project will also provide evidence
on the effects of CPWs in both urban and rural settings.
This is crucial to decision making as CPWs have not yet
been evaluated within Saskatchewan. Further, the inter-
vention will provide a rigorous evaluation of the use of
CPWs to improve care for COPD patients, adding to the
limited evidence base currently available. If the pathways
are found effective in both urban and rural settings, we
will work with all stakeholders to implement similar
CPWs across all areas of the province.
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